azn201505136k.htm

 
FORM 6-K


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


Report of Foreign Issuer


Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of May 2015
Commission File Number:  001-11960

AstraZeneca PLC

2 Kingdom Street, London W2 6BD

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X            Form 40-F  __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):            

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  __                 No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):   82-_____________
 
 
 
 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
   
1. Identity of the issuer or the underlying issuer
of existing shares to which voting rights are
attached: ii
AstraZeneca PLC
2 Reason for the notification (please tick the appropriate box or boxes):
An acquisition or disposal of voting rights
   X
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
  
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments
  
An event changing the breakdown of voting rights
  
Other (please specify):
    
3. Full name of person(s) subject to the
notification obligation: iii
The Capital Group Companies, Inc.
4. Full name of shareholder(s)
(if different from 3.):iv
See Schedule A
5. Date of the transaction and date on
which the threshold is crossed or
reached: v
11 May 2015
6. Date on which issuer notified:
12 May 2015
 
7. Threshold(s) that is/are crossed or
reached: vi, vii
Above 3%
         
 
8. Notified details:
A: Voting rights attached to shares viii, ix
Class/type of
shares
 
if possible using
the ISIN CODE
Situation previous
to the triggering
transaction
Resulting situation after the triggering transaction
Number
of
Shares
Number
of
Voting
Rights
Number
of shares
Number of voting
rights
% of voting rights x
Direct
Direct xi
Indirect xii
Direct
Indirect
Ordinary Shares
(ISIN: GB0009895292)
32,100,333
32,100,333
    
32,139,533
  
2.544%
ADRs
(ISIN: US0463531089)
5,767,760
5,767,760
    
5,768,891
  
0.457%
 
B: Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial
instrument
Expiration
date xiii
Exercise/
Conversion Period xiv
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
% of voting
rights
         
 
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi
Resulting situation after the triggering transaction
Type of financial
instrument
Exercise price
Expiration date xvii
Exercise/
Conversion period xviii
Number of voting rights instrument refers to
% of voting rights xix, xx
         
Nominal
Delta
   
 
Total (A+B+C)
Number of voting rights
Percentage of voting rights
37,908,424
3.000%
                                 
 
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
See Schedule A
 
Proxy Voting:
10. Name of the proxy holder:
  
11. Number of voting rights proxy holder will cease
to hold:
  
12. Date on which proxy holder will cease to hold
voting rights:
  
 
 
13. Additional information:
  
14. Contact name:
Martin Bennett, Assistant Company Secretary
15. Contact telephone number:
020 7604 8157
     
 
 
Schedule A
 
As of 11 May 2015
 
AstraZeneca PLC
 
 
Number of Shares
Percent of Outstanding
     
The Capital Group Companies, Inc. ("CG") holdings
37,908,424
3.000%
Holdings by CG Management Companies and Funds:
    
Capital Guardian Trust Company
5,439,762
0.431%
Capital International Limited
165,000
0.013%
Capital International Sàrl
153,792
0.012%
Capital International, Inc.
72,300
0.006%
Capital Research and Management Company
32,077,570
2.539%

 
 

SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC




Date: 13 May 2015
By:  /s/ Adrian Kemp
 
Name: Adrian Kemp
 
Title: Company Secretary